• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺动脉高压的定义、流行病学及登记系统

Definition, epidemiology and registries of pulmonary hypertension.

作者信息

Awdish R, Cajigas H

机构信息

Henry Ford Health System, Detroit, MI, USA.

出版信息

Heart Fail Rev. 2016 May;21(3):223-8. doi: 10.1007/s10741-015-9510-y.

DOI:10.1007/s10741-015-9510-y
PMID:26438630
Abstract

Pulmonary arterial hypertension (PAH) is a subcategory of pulmonary hypertension (PH) that comprises a group of disorders with similar pulmonary vascular pathology. Though PH is common, the estimated incidence of IPAH is 1-3 cases per million, making it a rare disease. The hemodynamic definition of PAH is a mean pulmonary artery pressure at rest >OR = 25 mm Hg in the presence of a pulmonary capillary wedge pressure <OR = 15 mmHg with pulmonary vascular resistance (PVR) greater than 3 WU. Specific maneuvers during right heart catheterization can be utilized to disclose vasoreactivity and heart failure with preserved ejection fraction, which have implications for management. The inherent complexity in studying a rare disease that exhibits clinical overlap with a common syndrome necessitated the creation of registries. These registries have been indispensable in the characterization and mapping of the natural history of the disease. Equations and risk calculators derived from registries have given clinicians a basis for risk stratification and prognostication. The sequential accumulation of data since the registries began in the 1980s allows for comparisons to be made. Patients who are differentiated by treatment eras and environments can be contrasted. Variability among inclusion criteria similarly allows for comparisons of these subpopulations. This article provides an overview of available registries, highlights insights provided by each and discusses key issues around the interpretation and extrapolation of data from PAH registries. Registries have allowed us to appreciate the improvement in survival afforded by modern therapy and enhanced detection of this disease. Moving forward, a more global approach to registries is needed, as is enhanced collaboration and centralization.

摘要

肺动脉高压(PAH)是肺动脉高压(PH)的一个亚类,它包含一组具有相似肺血管病理特征的疾病。尽管PH很常见,但特发性肺动脉高压(IPAH)的估计发病率为每百万人口中有1 - 3例,使其成为一种罕见疾病。PAH的血流动力学定义为静息时平均肺动脉压≥25 mmHg,同时肺毛细血管楔压≤15 mmHg,且肺血管阻力(PVR)大于3个伍德单位(WU)。右心导管检查期间的特定操作可用于揭示血管反应性以及射血分数保留的心力衰竭情况,这对治疗管理具有重要意义。研究一种与常见综合征存在临床重叠的罕见疾病存在内在复杂性,因此有必要建立登记系统。这些登记系统对于描述该疾病的自然史和绘制其图谱而言必不可少。从登记系统得出的方程和风险计算器为临床医生进行风险分层和预后判断提供了依据。自20世纪80年代登记系统开始以来数据的逐步积累使得进行比较成为可能。可以对比不同治疗时代和环境下的患者。纳入标准的差异同样使得对这些亚人群进行比较成为可能。本文概述了现有的登记系统,突出了每个系统所提供的见解,并讨论了围绕PAH登记系统数据解读和外推的关键问题。登记系统使我们能够认识到现代治疗所带来的生存率提高以及对该疾病检测的增强。展望未来,需要一种更具全球性的登记系统方法,同时也需要加强协作和集中化。

相似文献

1
Definition, epidemiology and registries of pulmonary hypertension.肺动脉高压的定义、流行病学及登记系统
Heart Fail Rev. 2016 May;21(3):223-8. doi: 10.1007/s10741-015-9510-y.
2
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.美国肺动脉高压患者的变化情况:REVEAL 与历史和非美国当代注册研究的不同之处。
Chest. 2011 Jan;139(1):128-37. doi: 10.1378/chest.10-0075. Epub 2010 Jun 17.
3
Pulmonary arterial hypertension: epidemiology and registries.肺动脉高压:流行病学和注册研究。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023.
4
Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).先天性心脏病相关肺动脉高压患者的 4 年和 7 年结局(来自 REVEAL 登记研究)。
Am J Cardiol. 2014 Jan 1;113(1):147-55. doi: 10.1016/j.amjcard.2013.09.032. Epub 2013 Oct 4.
5
Definitions and diagnosis of pulmonary hypertension.肺动脉高压的定义和诊断。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032.
6
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.肺动脉高压:REVEAL 注册研究的基线特征。
Chest. 2010 Feb;137(2):376-87. doi: 10.1378/chest.09-1140. Epub 2009 Oct 16.
7
Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension).肺动脉高压患儿的血流动力学特征及心导管插入术并发症:来自全球TOPP注册研究(追踪儿科肺动脉高压的结局和实践)的见解
Int J Cardiol. 2016 Jan 15;203:325-30. doi: 10.1016/j.ijcard.2015.10.087. Epub 2015 Oct 23.
8
Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes.由左心疾病导致的肺动脉高压:根据 2015 ESC/ERS 指南血流动力学分类的生存分析及对未来变化的见解。
Eur J Heart Fail. 2018 Feb;20(2):248-255. doi: 10.1002/ejhf.860. Epub 2017 May 2.
9
Pulmonary arterial hypertension in France: results from a national registry.法国肺动脉高压:一项全国性登记研究的结果
Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30. doi: 10.1164/rccm.200510-1668OC. Epub 2006 Feb 2.
10
Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system.右心导管检查在左心疾病相关肺动脉高压患者诊断及风险分层中的局限性:来自无线肺动脉压力监测系统的见解
J Heart Lung Transplant. 2015 Mar;34(3):438-47. doi: 10.1016/j.healun.2015.01.983. Epub 2015 Feb 7.

引用本文的文献

1
Morbidity and Mortality Associated With Pulmonary Arterial Hypertension in a Schistosomiasis-Endemic Region of Brazil.巴西血吸虫病流行地区肺动脉高压相关的发病率和死亡率
Pulm Circ. 2025 Apr 27;15(2):e70086. doi: 10.1002/pul2.70086. eCollection 2025 Apr.
2
Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.肺动脉高压患者的生存、发病率和生活质量:基于人群的观察性研究报告结局的系统评价。
Respir Res. 2024 Oct 16;25(1):373. doi: 10.1186/s12931-024-02994-w.
3
Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.

本文引用的文献

1
Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases.南半球的肺动脉高压:巴西新发病例登记研究结果
Chest. 2015 Feb;147(2):495-501. doi: 10.1378/chest.14-1036.
2
Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure.肺动脉压轻度升高患者的临床特征和生存情况。
Pulm Circ. 2013 Dec;3(4):916-25. doi: 10.1086/674756.
3
Pulmonary arterial hypertension: epidemiology and registries.肺动脉高压:流行病学和注册研究。
内皮素受体拮抗剂致肝损伤:基于上市后药物监测数据的真实世界研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666231223606. doi: 10.1177/17534666231223606.
4
The impact of the COVID-19 pandemic on the care of pulmonary hypertension patients outside the Hubei province in China.新型冠状病毒肺炎疫情对中国湖北省以外地区肺动脉高压患者护理的影响。
Pulm Circ. 2022 Jul 1;12(3):e12130. doi: 10.1002/pul2.12130. eCollection 2022 Jul.
5
Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.肺动脉高压的患病率、发病率和生存率:2020年全球疾病负担研究的系统评价
Pulm Circ. 2022 Jan 18;12(1):e12020. doi: 10.1002/pul2.12020. eCollection 2022 Jan.
6
Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.一氧化碳弥散能力作为肺动脉高压严重程度的标志物
J Clin Med. 2021 Dec 27;11(1):132. doi: 10.3390/jcm11010132.
7
Pulmonary hypertension: From an orphan disease to a global epidemic.肺动脉高压:从罕见病到全球流行病。
Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202005. doi: 10.21542/gcsp.2020.5.
8
Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.在临床实践中,使用马西替坦治疗肺动脉高压患者的 REVEAL 风险评分变化:PRACMA 研究结果。
BMC Pulm Med. 2020 Jun 2;20(1):154. doi: 10.1186/s12890-020-01197-5.
9
High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude.肺动脉高压的高地域患病率:与种族、药物使用及海拔的关联
Pulm Circ. 2020 Feb 4;10(1):2045894019894534. doi: 10.1177/2045894019894534. eCollection 2020 Jan-Mar.
10
Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL).肺动脉高压患者的特征:来自波兰肺动脉高压登记处(BNP-PL)的数据。
J Clin Med. 2020 Jan 8;9(1):173. doi: 10.3390/jcm9010173.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023.
4
Definitions and diagnosis of pulmonary hypertension.肺动脉高压的定义和诊断。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032.
5
Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure.快速盐水负荷对血流动力学的反应:年龄、性别和心力衰竭的影响。
Circulation. 2013 Jan 1;127(1):55-62. doi: 10.1161/CIRCULATIONAHA.112.111302. Epub 2012 Nov 21.
6
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry.老年特发性肺动脉高压患者:COMPERA 注册研究结果。
Int J Cardiol. 2013 Sep 30;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026. Epub 2012 Nov 17.
7
Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.诊断为肺动脉高压且肺毛细血管楔压为 16 至 18mmHg 的患者的人口统计学和结局:来自 REVEAL 登记研究的见解。
Chest. 2013 Jan;143(1):185-195. doi: 10.1378/chest.11-1387.
8
Predicting survival in pulmonary arterial hypertension in the UK.预测英国肺动脉高压患者的生存率。
Eur Respir J. 2012 Sep;40(3):604-11. doi: 10.1183/09031936.00196611. Epub 2012 May 3.
9
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.特发性肺动脉高压患者血流动力学正常与边缘平均肺动脉压患者的基线特征及随访:PHAROS 注册研究结果。
Ann Rheum Dis. 2012 Aug;71(8):1335-42. doi: 10.1136/annrheumdis-2011-200546. Epub 2012 Feb 2.
10
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.从 REVEAL 注册研究评估肺动脉高压诊断后患者的长期生存。
Chest. 2012 Aug;142(2):448-456. doi: 10.1378/chest.11-1460.